Mainz Biomed (NASDAQ: MYNZ) is stacking up a killer catalyst calendar, and I'm feeling the buzz heading into Q4 2025! The finance card above shows it at $1.56, up a smidge today. Top-line from eAArly DETECT 2 drops Q4, with UK onboarding and Swiss adoption ramping - think lab rollouts, orders, and usage metrics turning "potential" into cash. Germany's CARE payer ties and GANZIMMUN nationwide push add steady EU flow, prepping ReconAAsense's 2026 US kickoff. Oh, and they nailed Nasdaq compliance back in Jan 2025, ditching that overhang.

Trading-wise, that Aug 4 follow-on at $1.35 (with warrants) is like a psychological floor - micro-biotechs love those memory levels, especially with Europe firing. Fresh off their H1 2025 update accelerating FDA paths and PancAlert expansion, plus tomorrow's Oct 3 WEO presentation in Berlin on CRC screening tech, this feels like the setup for multi-year upside. What Q4 data would lock in your long thesis - strong sensitivity/specificity or early EU revenue beats?









  
DSS PBFS NUVB TLSI SPHL ONCY RMSG GILT ADPT VRAR PULM SUPX WKSP VRSN PHAT MSAI HIMS VGZ PFE GPUS NUWE CRWD QUBT UBER NFLX ASIC INV KDK KRRO EMPG SNDL RKDA AMAT ZURA VIVK BCAX ORKA STEX JFB BAFN BENF BYND AXIL TAOP FSEA NUAI OLB UPB BANL HUHU EHTH IRBT BMNR GOVX SNPS CLRO ESBA CASI CORZ AUID WNW QCLS MRUS NBY BA APLT BE JPM MELI RYM META GEV SOS SELX MGRX SOFI FOFO CEG MFH CCL HXHX PRGS DFLI FLYX PAVS ALAB MTEK COOT PSTV FLY POCI FLUT VOR SNWV IQST NTWK OXY FBGL SNOW DNA CYCN HOOD KRMN REFR SPRC CHOW CRE IROH CJET PYPL PAYS IBM AMST CMDB MGN CRCL CRCT ITP DRDB LLY

MYNZ's Tight Calendar: Q4 Data + $1.35 Memory Level?